Relapsed or Refractory Classical Hodgkin Lymphoma
Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) is a type of cancer that affects the lymphatic system, where the disease returns after treatment or does not respond to initial therapy.
Lymphoma Treatment: MK-3475A Study
We are testing a new formulation of pembrolizumab for patients with relapsed or refractory classical Hodgkin lymphoma or primary mediastinal large B-cell lymphoma. The study aims to evaluate its effectiveness and safety compared to existing treatments.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma
Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) is a type of aggressive lymphoma that occurs in the mediastinum and can return after treatment or resist initial therapy.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 18 and 75 years old?
- Do you have a diagnosis of classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma?
- Do you have any active heart problems or significant cardiovascular disease?
- Are you currently taking any cancer treatments like chemotherapy or immunotherapy?
- Have you had any major infections that required treatment in the last month?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Mk-3475A
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Universitaetsklinikum Essen AöR
Klinik für Hämatologie WTZ-Forschungsgebäude, 2.OG, R2.57 Westdeutsches Tumorzentrum Essen
Essen, Germany
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
Klinika Transplantacji Szpiku i Onkohematologii
Gliwice, Poland
Pratia S.A.
Pratia MCM Kraków
Grzegórzki, Poland
Sponsor: Merck Sharp & Dohme LLC
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.